Population-based Age-stratified Seroepidemiological Investigation Protocol for Coronavirus 2019 (COVID-19) Infection in the Federation of Bosnia and Herzegovina

NCT05124535 | Unknown

• 1 other identifier: 001
• Study Type: observational
• Target: 1,152
• Locations: 1 country
• Sites: 1

Brief Summary

This study is the second cross-sectional study conducted in the region. In the first cross sectional study, conducted in the winter of 2020, we aimed to estimate the seroprevalence of SARS-CoV-2 IgG antibodies among blood donors in Sarajevo Canton. We also assessed immune durability among seropositive participants after 6 months. In total, of 1015 blood donors aged 18-65 years in Sarajevo Canton between 2 November and 3 December 2020 were recruited and population-weighted seroprevalence in Sarajevo Canton was 19.2% (95% CI: 16.7-21.6%). The aim of this second cross-sectional study is to measure the seroprevalence SARS-CoV-2 antibodies and assess antibody kinetics in the blood donor population after 12 months.

Conditions

Seroprevalence; Antibody; COVID-19

Outcome Measures

Primary Outcomes (1)

• Seroprevalence of SARS-CoV-2 IgG antibodies

  Crude seroprevalence among blood donors will be adjusted to age and sex distribution in cantonal population and to test sensitivity and specificity using Bayesian statistical modeling.

  November 2021-December 2021

Secondary Outcomes (2)

• Assess factors associated with seropositivity.

  November 2021-December 2021

• Assess antibody response across types of immunity.

  November 2021-December 2021

Study Arms (3)

Persons aged 18-29

Persons aged 30-39

Persons aged 40-65

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Recruitment will be convenience sampling of blood donors aged between 18 and 65 years. All blood donors visiting the Institute for Transfusion Medicine of the Federation of Bosnia and Herzegovina for routine blood donation will be approached during the study period to participate in the study by the staff (medical doctors) of Institute for Transfusion Medicine of the Federation of Bosnia and Herzegovina at time of donation. Some blood donors will also be called by the staff of the Institute for Transfusion Medicine during the routine actions for donation of missing blood types, from an existing list maintained by staff at the Institute for Transfusion Medicine, and will be also invited to participate in the study by staff upon attendance at the blood clinic. Investigators will endeavor to ensure that the following three age groups can be reported: 18-29, 30-39, 40-65.

You may qualify if:

• All individuals identified for recruitment into the investigation, resident of Canton Sarajevo between 18-65 years, irrespective of prior COVID-19 infection.

You may not qualify if:

• Refusal to give informed consent or to attend follow-up appointments; currently experiencing COVID-19 symptoms or in the last 14 days; and close contact with a confirmed case of COVID-19 within 14 days prior to donation.

Sponsors & Collaborators

• Institute for Public Health of the Federation of Bosnia and Herzegovina: lead
• World Health Organization: collaborator

Study Sites (1)

Institute for Transfusion Medicine of the Federation of Bosnia and Herzegovina

Sarajevo, 71000, Bosnia and Herzegovina

Location

Related Publications (1)

• Musa S, Catovic Baralija E, Ivey Sawin V, Nardone A, Palo M, Skocibusic S, Blazevic M, Cilovic Lagarija S, Ahmetovic-Karic G, Ljuca A, Dostovic-Halilovic S, Nedic R, Subissi L, Ibrahim R, Boshevska G, Bergeri I, Pebody R, Vaughan A. Evolution of seroprevalence to SARS-CoV-2 in blood donors in Sarajevo Canton, Federation of Bosnia and Herzegovina: Cross-sectional and longitudinal studies. Influenza Other Respir Viruses. 2023 Aug 22;17(8):e13182. doi: 10.1111/irv.13182. eCollection 2023 Aug.

  PMID: 37621919 DERIVED

MeSH Terms

Conditions

COVID-19

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases

Central Study Contacts

Veronica I Sawin, ScM

CONTACT

+38762022240; viveysawin@gmail.com

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: CROSS SECTIONAL
• Sponsor Type: OTHER GOV
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 16, 2021
• First Posted: November 18, 2021
• Study Start: November 17, 2021
• Primary Completion: December 31, 2021
• Study Completion: December 31, 2021
• Last Updated: November 18, 2021

Record last verified: 2021-11

Locations

BO (1)